Overview

Intravitreal Conbercept After Vitrectomy

Status:
Completed
Trial end date:
2019-02-28
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of intravitreal conbercept after vitrectomy for the management of early-stage proliferative diabetic retinopathy (PDR). Hypothesis: intravitreal conbercept therapy may promote functional and anatomic recovery from PDR. intravitreal conbercept therapy may be a useful and safe method for improving visual outcomes of surgery for early-stage PDR.
Phase:
Early Phase 1
Details
Lead Sponsor:
Tianjin Medical University Eye Hospital